As PHLPP is lost in a majority of colon cancer patients26,29 and PHLPP loss renders cancer cells sensitive to glucose restriction-induced cell death, selectively targeting HK2 (such as using agents that dissociate HK2 from mitochondria) may provide a novel treatment option for colon cancer patients. Here, PHLPP1 is linked to cancer.